https://www.ncbi.nlm.nih.gov/pubmed/30575484
The New England Journal of Medicine; Gounder MM, Mahoney MR et. al.
Dec 21st, 2018 - Desmoid tumors (also referred to as aggressive fibromatosis) are connective tissue neoplasms that can arise in any anatomical location and infiltrate the mesentery, neurovascular structures, and visceral organs. There is no standard of care. In this double-blind, phase 3 trial, we randomly assigned 87 patients with progressive, symptomatic, or recurrent desmoid tumors...
https://www.mdedge.com/oncologypractice/article/191511/rare-diseases/sorafenib-extends-pfs-refractory-desmoid-tumors
Neil Osterweil, Oncology Practice
Dec 19th, 2018 - For patients with progressive, refractory, or symptomatic desmoidtumors – also known as aggressive fibromatosis – treatment with daily sorafenib(Nexavar) was associated with durable responses and a significant improvement in progression-free survival. After a median follow-up of 27.
https://www.medpagetoday.com/hematologyoncology/othercancers/77032
Dec 19th, 2018 - Treatment with sorafenib (Nexavar) induced durable responses and doubled the rate of progression-free survival (PFS) at 2 years in patients with advanced or refractory desmoid tumors, results of a double-blind phase III trial found. Among 84 evaluable patients with symptomatic, progressive, or refractory tumors, the estimated 2-year PFS rate was 81% in the sorafen...
https://www.medpagetoday.com/hematologyoncology/othercancers/77101
Dec 21st, 2018 - Action Points In this double-blind, randomized, placebo-controlled Phase III trial of sorafenib (Nexavar) in patients with advanced desmoid tumors, the 2-year progression-free survival rate at 27.2 months was 81% vs 36% for placebo. There is currently no accepted standard of care for desmoid tumors, so the results from this trial with sorafenib may lead...
https://www.medscape.com/viewarticle/897781
Jun 8th, 2018 - NEW YORK (Reuters Health) - Sorafenib boosts progression-free survival among patients with desmoid tumors, according to results of a new phase 3 trial. "Sorafenib now represents a very reasonable choice for first-line therapy for patients with desmoid tumors," said Dr. Gary Schwartz of Columbia University School of Medicine in New York, the study's seni...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου